Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics
The DOI matches its Crossref record; 282 of the 283 references it cites were found in a registry or an index.
Abstract
The clinical use of tricyclic antidepressants (TCAs) is often complicated by toxicity and safety problems due to their effects on multiple mechanisms of action, many of which are unnecessary for therapeutic effect. The development of the selective serotonin reuptake inhibitors (SSRIs), with their selective mode of action, has resulted in a class of antidepressant drugs possessing an improved side-effect profile, while retaining good clinical efficacy. Their introduction into clinical practice has led to enhanced patient compliance with antidepressant therapy and the ability to maintain treatment over longer periods of time at an adequate therapeutic dose. Although, as a result of their selective action, side-effects associated with SSRI therapy are minimised, distinct variations between individual SSRIs in terms of their tolerability profiles have been observed. The wealth of clinical data now available has revealed differences in their potential to cause psychiatric and neurological side-effects, dermatological reactions, anticholinergic side-effects, changes in body weight, sexual dysfunction, cognitive impairment, discontinuation reactions and drug-drug interactions. Patients who suffer from concomitant depression and physical illness may experience different tolerability profiles, in addition to the greater likelihood that they will be receiving concomitant medications with the potential for pharmacokinetic drug-drug interactions with coadministered SSRI therapy. In addition, the safety margin of SSRIs in overdose may vary within the group. Knowledge of the differences that exist among the SSRIs in respect of tolerability and safety will aid physicians in the selection of the most beneficial treatment strategy for their patients. A successful clinical outcome leads to a reduced economic burden for the patient, their family and the healthcare services. Thus, pharmacoeconomic considerations are also important in choosing antidepressant therapy. The SSRIs, despite relatively higher prescription costs, have been demonstrated to be a more cost-effective option than the TCAs. Furthermore, there is evidence that the emerging clinical differences between SSRIs may translate into significantly different economic outcomes within the group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“their clinical efficacy develops only after chronic treatment (Goldstein and Goodnick, 1998; Gorman et al, 1987).”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Goldstein and Goodnick, 1998
In the citing paper
“initial treatment with SSRIs can have effects opposite to those seen after chronic treatment, eg, anxiogenic rather than anxiolytic effects (Goldstein and Goodnick, 1998; Gorman et al, 1987).”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Goldstein and Goodnick, 1998
In the citing paper
“Such chronic dosing paradigms inevitably lead to a host of undesirable side-effects that include weight gain, sexual dysfunction, and gastrointestinal problems”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [299]
Citations
Cites
Structure and function of the brain serotonin system
Jacobs, B. L., & Azmitia, E. C. (1992) · Physiological Reviews · doi:10.1152/physrev.1992.72.1.165 · Cited by 2,576
Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction
(1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270403 · Cited by 1,005
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
(1998) · PubMed · doi:10.1176/ajp.155.3.344 · Cited by 784
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Emergence of intense suicidal preoccupation during fluoxetine treatment
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.207 · Cited by 532 · cited 1×
“It was suggested that egodystonic suicidality may be associated with SSRI-induced akathisia (Lipinski et al., 1989; Teicher et al., 1990; Rothschild and Locke, 1991; Hamilton and Opler, 1992; Lavin et al., 1993).”
BackgroundAdequacy and Duration of Antidepressant Treatment in Primary Care
Katon, W., Von Korff, M., Lin, E., Bush, T., & Ormel, J. (1992) · Medical Care · doi:10.1097/00005650-199201000-00007 · Cited by 513
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505
Benfield, P., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632040-00002 · Cited by 494
Induction of Mania with Selective Serotonin Re-uptake Inhibitors and Tricyclic Antidepressants
Peet, M. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.4.549 · Cited by 474
Research works printed but not linked: 153
- 1996, Austr Adverse Drug Reactions Bull, 15, 3
- New Research Abstracts American Psychiatric Association Annual Meeting
- 1983, J Affect Disord, 51, 15
- 1994, Review of the literature. Encéphale, 20, 65
- 1993, JAMA, 269, 869
- 1994, J Clin Psychiatry, 55, 394
- 1998, J Affect Disord, 46, 151
- 1996, Aus NZ J Psychiatry, 30, 702
- 1991, Am J Psychiatry, 148, 274
- 1993, J Clin Psychiatry, 54, 115
- 1989, Acta Psychiatr Scand, 80, 102
- 1993, J Clin Psychopharmacol, 13, 312
- 1996, J Clin Psychiatry, 57, 93
- 1995, J Clin Psychiatry, 56, 229
- 1996, J Clin Psychiatry, 57, 93
- 1993, Clin Pharmacol Ther, 1, 84
- 1994, Curr Affective Illness, 13, 14
- 1996, Eur Neuropsychopharmacol, 6, 122
- 1993, J Clin Psychiatry, 54, 146
- 1996, Encephale, 22, 221
- Boyer W.F., Feighner J.P. (1991) Pharmacokinetics and drug interactions. In Feighner J P, Boyer W F (eds), Perspectives in psychiatry, vol. 1. Selective serotonin reuptake inhibitors. John Wiley & Sons, Chichester, pp. 81-88.
- Poster presented at the 148th Annual Meeting of the American Psychiatric Association
- 1995, J Clin Psychiatry, 56, 30
- 1998, Praxis, 87, 345
- 1991, J Clin Psychiatry, 52, 174
- Bunney W.E. (1978) Psychopharmacology of the switch process in affective illness. In Lipton M A, DiMascio A, Kellam K F (eds), Psychopharmacology: a generation of progress. Raven Press, New York, pp.1249-1259.
- 1994, Citalopram product monograph
- 1992, J Clin Psychiatry, 53, 272
- 1992, J Clin Psychiatry, 53, 278
- 1994, Neuropsychopharmacology, 10, 222S
- 1993, Curr Prob, 19, 1
- 1988, Br J Psychiatry, 3, 77
- 1996, Sexual pharmacology: drugs that affect sexual functioning
- 1994, J Clin Psychopharmacol, 14, 340
- 1996, Br J Psychiatry, 68, 164
- 1995, Am J Psychiatry, 152, 1253
- 1990, J Clin Psychiatry, 51, 385
- 1996, J Clin Psychopharmacol, 16, 37S
- 1997, Encephale, 23, 39
- 1993, Summary basis of approval for Paxil (paroxetine)
- 1991, J Clin Psychiatry, 52, 163
- 1993, Scand J Gastroenterology, 28, 40
- 1996, J Clin Psychiatry, 57, 53
- 1994, Neuropsychopharmacology, 10, 165S
- New Research Program Abstracts American Psychiatric Association Annual Meeting
- 1996, J Clin Psychiatry, 57, 23
- 1996, Psychopharmacol Bull, 32, 653
- 1994, Eur J Pharmacol, 46, 35
- 1991, West J Med, 155, 522
- 1993, JAMA, 270, 1860, 10.1001/jama.1993.03510150094038 · doi:10.1001/jama.1993.03510150094038
- 1993, Br J Clin Res, 4, 145
- 1997, Clin Pharmacokinet, 32, 43
- 1987, J Clin Psychopharmacol, 7, 329
- 1992, J Clin Psychiatry, 53, 401
- 1988, Psychopharmacol Bull, 24, 220
- 1992, Eur J Med, 1, 343
- 1990, J Clin Psychiatry, 51, 25
- 1990, J Clin Psychiatry, 51, 34
- 1990, J Clin Psychopharmacol, 10, 343
- 1991, J Clin Psychiatry, 52, 131
- 1997, J Clin Outcome Management, 4, 16
- 1993, Nord J Psychiatry, 47, 5
- 1992, J Clin Psychiatry, 53, 119
- 1981, Acta Psychiatr Scand, 63, 447
- 1996, Eur Neuropsychopharmacol, 6, 143
- 1995, J Med Assoc Thailand, 78, 53
- 1992, Vet Hum Toxicol, 34, 343
- 1996, Formulary, 31, 374
- 1994, J Clin Psychiatry, 55, 137
- 1992, J Clin Psychiatry, 53, 127
- 1994, Am J Geriatr Psychiatry, 2, 271
- 1992, Int Clin Psychopharmacol, 7, 101
- 1997, Clin Pharmacol Therap, 61, 178
- 1996, International Clin Psychopharmacol, 11, 31
- 1996, J Serotonin Res, 3, 75
- 1998, J Psychopharmacol, 12, 208
- 1995, J Serotonin Res, 3, 171
- New Research Program and Abstracts. Paper presented at the 148th Annual Meeting of the American Psychiatric Association
- 1996, Eur Neuropsychopharmacol, 6, 124
- 1987, Am J Psychiatry, 144, 16
- 1994, CNS Drugs, 2, 132
- 1995, Eur J Clin Res, 7, 287
- Poster presented at the 148th Annual Meeting of the American Psychiatric Association
- 1993, J Clin Psychopharmacol, 13, 175
- 1989, J Clin Psychiatry, 50, 339
- 1998, Br J Psychiatry, 183
- 1989, South African Med J, 82, 933
- 1996, Scotland. Br Med J, 313, 860
- 1995, J Clin Psychiatry, 56, 82
- 1988, J Clin Psychiatry, 49, 52
- 1990, J Clin Psychiatry, 51, 60
- 1995, J Clin Psychiatry, 56, 49
- 1996, Eur Neuropsychopharmacol, 6, 36
- Poster presented at the BAP/BNPA Summer Meeting
- Medical Economics Data (1997a) Prozac (fluoxetine hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 943-947.
- Medical Economics Data (1997b) Paxil (paroxetine hydrochloride) Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2681-2686.
- Medical Economics Data (1997c) Zoloft (sertraline hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2051-2053.
- Medical Economics Data (1997d) Effexor (venlafaxine hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co. Montvale, NJ, pp. 2825-2829. Medical Economics Data (1997e) Luvox (fluvoxamine maleate). Physicians desk reference (51st edn). Medical Economics Data Production Co. Montvale, NJ, pp. 2723-2726.
- New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association
- 1995, Am Fam Physician, 52, 1475
- 10.1002/(SICI)1099-1077(199609)11:5<365::AID-HUP815>3.0.CO;2-F · doi:10.1002/(sici)1099-1077(199609)11:5<365::aid-hup815>3.0.co;2-f
- Paper presented at the 148th Annual Meeting of the American Psychiatric Association
- 1993, Vet Hum Toxicol, 35, 341
- 1996, Eur Neuropsychopharmacol, 6, 35
- 1988, Neuropsychopharmacology, 27, 597602
- 1990, Arch Biochem Biophys, 276, 424432
- 1986, Br J Clin Pharmacol, 22, 97
- 1998, Clin Pharmacol Ther, 62, 334
- 1996, Int Clin Psychopharmacol, 11, 129
- 1994, Clin Pharmacol Ther, 54, 471
- 1992, Encephale, 18, 76
- Poster presented at 37th Annual New Clinical Drug Evaluation Unit Meeting
- 1995, Psychopharmacol Bull, 31, 327
- 1995, Clinical pharmacology of selective serotonin reuptake inhibitors
- Preskorn S.H., Janicak P.G., Davis J.M., Ayd F. Jr (1995) Advances in the pharmacotherapy of depressive disorders . In Janicak P G, Davis J M, Preskorn S H, Ayd FJ (eds), Principals and practice of psychopharmacotherapy. Williams & Wilkins, Baltimore, pp. 1-24.
- 1997, Psychopharmacol Bull, 33, 659
- 1998, Clin Pharmacol Therap, 63, 166
- 1996, J Clin Psychiatry, 57, 24
- 1996, J Clin Psychiatry, 57, 20
- 1994, J Clin Psychiatry, 55, 34
- 1998, Primary Psychiatry, 5, 40
- 1990, J Clin Psychiatry, 51, 9
- 1989, J Clin Psychiatry, 50, 12
- 1991, J Clin Psychiatry, 52, 491
- New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association
- New Research Abstracts American Psychiatric Association Annual Meeting
- 1995, Drugs, 4, 28
- 1994, Clin Ther, 16, 715
- 1993, J Clin Psychiatry Monograph, 11, 57
- 1991, Sleep Res, 20, 189
- 1997, J Clin Psychiatry, 58, 5
- 1994, J Clin Psychopharmacol, 14, 322
- 1996, Movement Disord, 11, 603
- 1997, Pharmacist, 22, 60
- 1997, Am J Man Care, 3, 125
- 1998, Eur J Clin Pharmacol, 53, 163
- 1988, Lancet, 2, 850
- New Research Program and Abstracts. Paper presented at the American Psychiatric Association 146th Annual Meeting
- 1998, Primary Psychiatry, 5, 28
- 1996, Am J Med, 101, 265
- 1993, J Clin Psychopharmacol, 13, 18S
- 1994, J Clin Psychopharmacol, 14, 163
- 1992, J Am Acad Child Adol Psychiatry, 31, 265
- 1998, Am J Psychiatry, 155, 344
- New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association
- 1983, Psychiatry Clin North Am, 5, 27
- 1996, J Clin Psychiatry, 57, 7
- 1994, Primary Psychiatry, 11, 22
- New Research Program and Abstracts American Psychiatry Association Annual Meeting
- 1991, Neuropsychopharmacology, 5, 43
- 1997, Psychopharmacol Bull, 33, 755
- 1987, Int J Obesity, 11, 191
- 1987, J Clin Psychopharmacol, 7, 254
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669
“Presumably, the discontinuation syndrome results from neurophysiologic readjustment in the central nervous system to compensate for the pharmacologic activity of the SSRI.”
BackgroundInfluentialCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Bourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408
Metadata
- Authors
- Goldstein, B. J., & Goodnick, P. J.
- Affiliations
- Health Services Research Center (Cyprus) (CY)
- University of Miami (US)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1998-07
- Volume
- 12
- Issue
- 4_suppl
- Pages
- 55-S87
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1889727824
- Cited by
- 171
- References
- 283
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 12 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 6 · 2014: 7 · 2013: 7 · 2012: 7
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- selective serotonin reuptake inhibitors, antidepressant tolerability, drug safety, pharmacoeconomics, tricyclic antidepressants, adverse drug reactions, drug-drug interactions, antidepressant overdose, cost-effectiveness, mood disorders, depression
- MeSH terms
- Humans, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. https://app.cochat.ai/papers/10.1177/0269881198012003041
- The paper
- Goldstein, B. J., & Goodnick, P. J. (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. Journal of Psychopharmacology. https://doi.org/10.1177/0269881198012003041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.